Differential Proteomics Identification of HSP90 as Potential Serum Biomarker in Hepatocellular Carcinoma by Two-dimensional Electrophoresis and Mass Spectrometry
The aim of the current study is to identify the potential biomarkers involved in Hepatocellular carcinoma (HCC) carcinogenesis. A comparative proteomics approach was utilized to identify the differentially expressed proteins in the serum of 10 HCC patients and 10 controls. A total of 12 significantly altered proteins were identified by mass spectrometry. Of the 12 proteins identified, HSP90 was one of the most significantly altered proteins and its over-expression in the serum of 20 HCC patients was confirmed using ELISA analysis. The observations suggest that HSP90 might be a potential biomarker for early diagnosis, prognosis, and monitoring in the therapy of HCC. This work demonstrates that a comprehensive strategy of proteomic identification combined with further validation should be adopted in the field of cancer biomarker discovery.
References
[1]
Parkin, DM. Global cancer statistics in the year 2000. Lancet Oncol？2001, 2, 533–543.
[2]
Cha, C; DeMatteo, RP; Blumgart, LH. Surgery and ablative therapy for hepatocellular carcinoma. J. Clin. Gastroenterol？2002, 35, S130–S137.
[3]
Shariff, MI; Cox, IJ; Gomaa, AI; Khan, SA; Gedroyc, W; Taylor-Robinson, SD. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis and therapeutics. Expert Rev. Gastroenterol Hepatol？2009, 3, 353–367.
[4]
Müller, C. Hepatocellular carcinoma-rising incidence, changing therapeutic strategies. Wien Med. Wochenschr？2006, 156, 404–409.
[5]
Mazzanti, R; Gramantieri, L; Bolondi, L. Hepatocellular carcinoma: Epidemiology and clinical aspects. Mol. Aspects Med？2008, 29, 130–143.
[6]
Pandey, A; Mann, M. Proteomics to study genes and genomes. Nature？2000, 405, 837–846.
[7]
Alessandro, R; Fontana, S; Kohn, E; De Leo, G. Proteomic strategies and their application in cancer research. Tumori？2005, 91, 447–455.
[8]
Koomen, JM; Haura, EB; Bepler, G; Sutphen, R; Remily-Wood, ER; Benson, K; Hussein, M; Hazlehurst, LA; Yeatman, TJ; Hildreth, LT; Sellers, TA; Jacobsen, PB; Fenstermacher, DA; Dalton, WS. Proteomic contributions to personalized cancer care. Mol. Cell. Proteomics？2008, 7, 1780–1794.
[9]
Peng, XQ; Wang, F; Geng, X; Zhang, WM. Current advances in tumor proteomics and candidate biomarkers for hepatic cancer. Expert Rev. Proteomics？2009, 6, 551–561.
Li, Z; Zhao, X; Bai, S; Wang, Z; Chen, L; Wei, Y; Huang, C. Proteomics identification of cyclophilin a as a potential prognostic factor and therapeutic target in endometrial carcinoma. Mol. Cell. Proteomics？2008, 7, 1810–1823.
[12]
Sagynaliev, E; Steinert, R; Nestler, G; Lippert, H; Knoch, M; Reymond, MA. Web-based data warehouse on gene expression in human colorectal cancer. Proteomics？2005, 5, 3066–3078.
[13]
Rabilloud, T. Two-dimensional gel electrophoresis in proteomics: Old, old fashioned, but it still climbs up the mountains. Proteomics？2002, 2, 3–10.
[14]
Mathivanan, S; Lim, JW; Tauro, BJ; Ji, H; Moritz, RL; Simpson, RJ. Proteomic analysis of A33-immunoaffinity-purified exosomes released from the human colon tumor cell line LIM1215 reveals a tissue-specific protein signature. Mol. Cell. Proteomics？2010, 9, 197–208.
[15]
Schulz, DM; B？llner, C; Thomas, G; Atkinson, M; Esposito, I; H？fler, H; Aubele, M. Identification of differentially expressed proteins in triple-negative breast carcinomas using DIGE and mass spectrometry. J. Proteome Res？2009, 8, 3430–3438.
[16]
Hongsachart, P; Huang-Liu, R; Sinchaikul, S; Pan, FM; Phutrakul, S; Chuang, YM; Yu, CJ; Chen, ST. Glycoproteomic analysis of WGA-bound glycoprotein biomarkers in sera from patients with lung adenocarcinoma. Electrophoresis？2009, 30, 1206–1220.
[17]
Cho, HJ; Baek, KE; Park, SM; Kim, IK; Choi, YL; Cho, HJ; Nam, IK; Hwang, EM; Park, JY; Han, JY; Kang, SS; Kim, DC; Lee, WS; Lee, MN; Oh, GT; Kim, JW; Lee, CW; Yoo, J. RhoGDI2 expression is associated with tumor growth and malignant progression of gastric cancer. Clin. Cancer Res？2009, 15, 2612–2619.
[18]
Vellaichamy, A; Sreekumar, A; Strahler, JR; Rajendiran, T; Yu, J; Varambally, S; Li, Y; Omenn, GS; Chinnaiyan, AM; Nesvizhskii, AI. Proteomic interrogation of androgen action in prostate cancer cells reveals roles of aminoacyl tRNA synthetases. PLoS One？2009, 4, e7075.
[19]
Ono, M; Matsubara, J; Honda, K; Sakuma, T; Hashiguchi, T; Nose, H; Nakamori, S; Okusaka, T; Kosuge, T; Sata, N; Nagai, H; Ioka, T; Tanaka, S; Tsuchida, A; Aoki, T; Shimahara, M; Yasunami, Y; Itoi, T; Moriyasu, F; Negishi, A; Kuwabara, H; Shoji, A; Hirohashi, S; Yamada, T. Prolyl 4-hydroxylation of alpha-fibrinogen: A novel protein modification revealed by plasma proteomics. J. Biol. Chem？2009, 284, 29041–29049.
[20]
Roessler, M; Rollinger, W; Mantovani-Endl, L; Hagmann, ML; Palme, S; Berndt, P; Engel, AM; Pfeffer, M; Karl, J; Bodenmüller, H; Rüschoff, J; Henkel, T; Rohr, G; Rossol, S; R？sch, W; Langen, H; Zolg, W; Tacke, M. Identification of PSME3 as a novel serum tumor marker for colorectal cancer by combining two-dimensional polyacrylamide gel electrophoresis with a strictly mass spectrometry-based approach for data analysis. Mol. Cell. Proteomics？2006, 5, 2092–2101.
[21]
Sun, Y; Mi, W; Cai, J; Ying, W; Liu, F; Lu, H; Qiao, Y; Jia, W; Bi, X; Lu, N; Liu, S; Qian, X; Zhao, X. Quantitative proteomic signature of liver cancer cells: Tissue transglutaminase 2 could be a novel protein candidate of human hepatocellular carcinoma. J. Proteome Res？2008, 7, 3847–3859.
[22]
Fujiyama, S; Tanaka, M; Maeda, S; Ashihara, H; Hirata, R; Tomita, K. Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology？2002, 62, 57–63.
Chromy, BA; Gonzales, AD; Perkins, J; Choi, MW; Corzett, MH; Chang, BC; Corzett, CH; McCutchen-Maloney, SL. Proteomic analysis of human serum by two-dimensional differential gel electrophoresis after depletion of high-abundant proteins. J. Proteome Res？2004, 3, 1120–1127.
[26]
Corzett, TH; Fodor, IK; Choi, MW; Walsworth, VL; Chromy, BA; Turteltaub, KW; McCutchen-Maloney, SL. Statistical analysis of the experimental variation in the proteomic characterization of human plasma by two-dimensional difference gel electrophoresis. J. Proteome Res？2006, 5, 2611–2619.
[27]
Hochstrasser, DF; Frutiger, S; Paquet, N; Bairoch, A; Ravier, F; Pasquali, C; Sanchez, JC; Tissot, JD; Bjellqvist, B; Vargas, R. Human liver protein map: A reference database established by microsequencing and gel comparison. Electrophoresis？1992, 13, 992–1001.
[28]
Zimmermann-Ivol, CG; Burkhard, PR; Le Floch-Rohr, J; Allard, L; Hochstrasser, DF; Sanchez, JC. Fatty acid binding protein as a serum marker for the early diagnosis of stroke: A pilot study. Mol. Cell. Proteomics？2004, 3, 66–72.
[29]
G？rg, A; Obermaier, C; Boguth, G; Weiss, W. Recent developments in two-dimensional gel electrophoresis with immobilized pH gradients: Wide pH gradients up to pH 12, longer separation distances and simplified procedures. Electrophoresis？1999, 20, 712–717.
[30]
G？rg, A; Obermaier, C; Boguth, G; Harder, A; Scheibe, B; Wildgruber, R; Weiss, W. The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis？2000, 21, 1037–1053.
[31]
Stasyk, T; Morandell, S; Bakry, R; Feuerstein, I; Huck, CW; Stecher, G; Bonn, GK; Huber, LA. Quantitative detection of phosphoproteins by combination of two-dimensional difference gel electrophoresis and phosphospecific fluorescent staining. Electrophoresis？2005, 26, 2850–2854.
[32]
Huang, HL; Stasyk, T; Morandell, S; Dieplinger, H; Falkensammer, G; Griesmacher, A; Mogg, M; Schreiber, M; Feuerstein, I; Huck, CW; Stecher, G; Bonn, GK; Huber, LA. Biomarker discovery in breast cancer serum using 2-D differential gel electrophoresis / MALDI-TOF/TOF and data validation by routine clinical assays. Electrophoresis？2006, 27, 1641–1650.
[33]
Sung, WK; Lu, Y; Lee, CW; Zhang, D; Ronaghi, M; Lee, CG. Deregulated direct targets of the hepatitis B virus (HBV) protein, HBx, identified through chromatin immunoprecipitation and expression microarray profiling. J. Biol. Chem？2009, 284, 21941–21954.
[34]
Kanda, M; Nomoto, S; Okamura, Y; Nishikawa, Y; Sugimoto, H; Kanazumi, N; Takeda, S; Nakao, A. Detection of metallothionein 1G as a methylated tumor suppressor gene in human hepatocellular carcinoma using a novel method of double combination array analysis. Int. J. Oncol？2009, 35, 4774–4783.
[35]
Motallebipour, M; Enroth, S; Punga, T; Ameur, A; Koch, C; Dunham, I; Komorowski, J; Ericsson, J; Wadelius, C. Novel genes in cell cycle control and lipid metabolism with dynamically regulated binding sites for sterol regulatory element-binding protein 1 and RNA polymerase II in HepG2 cells detected by chromatin immunoprecipitation with microarray detection. FEBS J？2009, 276, 187818–187890.
[36]
Chau, BN; Diaz, RL; Saunders, MA; Cheng, C; Chang, AN; Warrener, P; Bradshaw, J; Linsley, PS; Cleary, MA. Identification of SULF2 as a novel transcriptional target of p53 by use of integrated genomic analyses. Cancer Res？2009, 69, 1368–1374.
[37]
Wilkins, MR; Sanchez, JC; Gooley, AA; Appel, RD; Humphery-Smith, I; Hochstrasser, DF; Williams, KL. Progress with proteome projects: Why all proteins expressed by a genome should be identified and how to do it. Biotechnol. Genet. Eng. Rev？1996, 13, 19–50.
[38]
Anderson, L; Seilhamer, J. A comparison of selected mRNA and protein abundances in human liver. Electrophoresis？1997, 18, 533–537.
[39]
Hanash, SM. Biomedical applications of two-dimensional electrophoresis using immobilized pH gradients: Current status. Electrophoresis？2000, 21, 1202–1209.
[40]
Reymond, MA; Sanchez, JC; Hughes, GJ; Gunther, K; Riese, J; Tortola, S; Peinado, MA; Kirchner, T; Hohenberger, W; Hochstrasser, DF; Kockerling, F. Standardized characterization of gene expression in human colorectal epithelium by two-dimensional electrophoresis. Electrophoresis？1997, 18, 2842–2848.
[41]
Zhou, G; Li, H; DeCamp, D; Chen, S; Shu, H; Gong, Y; Flaig, M; Gillespie, JW; Hu, N; Taylor, PR; Emmert-Buck, MR; Liotta, LA; Petricoin, EF, III; Zhao, Y. 2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Mol. Cell. Proteomics？2002, 1, 117–124.
[42]
Isaacs, JS; Xu, W; Neckers, L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell？2003, 3, 213–217.
[43]
Gooljarsingh, LT; Fernandes, C; Yan, K; Zhang, H; Grooms, M; Johanson, K; Sinnamon, RH; Kirkpatrick, RB; Kerrigan, J; Lewis, T; Arnone, M; King, AJ; Lai, Z; Copeland, RA; Tummino, PJ. A biochemical rationale for the anticancer effects of Hsp90 inhibitors: Slow, tight binding inhibition by geldanamycin and its analogues. Proc. Natl. Acad. Sci. USA？2006, 103, 7625–7630.
[44]
Pascale, RM; Simile, MM; Calvisi, DF; Frau, M; Muroni, MR; Seddaiu, MA; Daino, L; Muntoni, MD; De Miglio, MR; Thorgeirsson, SS; Feo, F. Role of HSP90, CDC37, and CRM1 as modulators of P16(INK4A) activity in rat liver carcinogenesis and human liver cancer. Hepatology？2005, 42, 1310–1319.
[45]
Lang, SA; Moser, C; Fichnter-Feigl, S; Schachtschneider, P; Hellerbrand, C; Schmitz, V; Schlitt, HJ; Geissler, EK; Stoeltzing, O. Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice. Hepatology？2009, 49, 523–532.
[46]
Breinig, M; Caldas-Lopes, E; Goeppert, B; Malz, M; Rieker, R; Bergmann, F; Schirmacher, P; Mayer, M; Chiosis, G; Kern, MA. Targeting heat shock protein 90 with non-quinone inhibitors: A novel chemotherapeutic approach in human hepatocellular carcinoma. Hepatology？2009, 50, 102–112.
[47]
Zhang, H; Burrows, F. Targeting multiple signal transduction pathways through inhibition of Hsp90. J. Mol. Med？2004, 82, 488–499.
[48]
Pearl, LH; Prodromou, C; Workman, P. The Hsp90 molecular chaperone: An open and shut case for treatment. Biochem. J？2008, 410, 439–453.
[49]
Ma, Y; Peng, J; Huang, L; Liu, W; Zhang, P; Qin, H. Searching for serum tumor markers for colorectal cancer using a 2-D DIGE approach. Electrophoresis？2009, 30, 2591–1599.
[50]
Hinestrosa, MC; Dickersin, K; Klein, P; Mayer, M; Noss, K; Slamon, D; Sledge, G; Visco, FM. Shaping the future of biomarker research in breast cancer to ensure clinical relevance. Nat. Rev. Cancer？2007, 7, 309–315.
[51]
Ma, Y; Peng, J; Liu, W; Zhang, P; Huang, L; Gao, B; Shen, T; Zhou, Y; Chen, H; Chu, Z; Zhang, M; Qin, H. Proteomics identification of desmin as a potential oncofetal diagnostic and prognostic biomarker in colorectal cancer. Mol. Cell. Proteomics？2009, 8, 1878–1890.
